[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Europe Orphan Drug Pipeline Analysis 2014

January 2014 | 1430 pages | ID: E2FA3902AC5EN
PNS Pharma

US$ 2,400.00

E-mail Delivery (PDF), Hard Copy Mail Delivery, CD-ROM Mail Delivery

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Rare diseases are classified as those that affect fewer than 200,000 in the United States and less than 5 in 10,000 in the EU. The term “orphan” was associated with these drugs in order to reflect the lack of interest by pharma companies. In the European Union, orphan drugs are known as orphan medicinal products. Many treatments which are commercially available in today’s world lack the ability to address most of the rare disease indications. This throws open significant potential and opportunities in the European Union and other regions of the world which are currently untapped.

The rare diseases normally include certain cancers, metabolic conditions, diseases of the nervous system and musculoskeletal disorders, which are extremely life-threatening and impact lesser than 5 people in every 10,000 people. However, as a group, these diseases together could possibly affect close to 30 million people directly or indirectly in Europe. This shows the significant of the need to develop an increasing number of orphan medicinal products in the European region.

“Europe Orphan Drug Pipeline Analysis 2014” by PNS Pharma gives comprehensive insight on the various orphan designated drugs being developed in Europe. Research report covers all orphan designated drugs being developed in various clinical phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Europe orphan designated drug market based upon development process.

Following parameters for each drug profile in development phase are covered in “Europe Orphan Drug Pipeline Analysis 2014” research report:
  • Drug Profile Overview
  • Active Indication
  • Phase of Development
  • Country for Clinical Trial
  • Owner / Originator/ Licensee/Collaborator
  • Administrative Route
  • Drug Class
  • Patent Information
  • Molecular Formula
  • Brand Names
  • Development Agreements
  • ATC Codes
Number of Orphan Designated Drugs in Pipeline by Clinical Phase:
  • Preclinical: 35
  • Clinical: 2
  • Phase-I: 27
  • Phase-I/II: 49
  • Phase-II: 92
  • Phase-II/III: 16
  • Phase-III: 86
  • Preregistration: 24
  • Registered: 21
  • Marketed: 75
  • Unknown: 1
  • No Development Reported: 5
  • Suspended: 6
  • Discontinued: 80
  • Application Withdrawn: 4
1. EUROPE ORPHAN DRUG MARKET OVERVIEW

1.1 Orphan Drug Market Intoduction
1.2 Factors Driving Popularity of Orphan Drugs in Europe
1.3 Orphan Drug Market Challenges
1.4 Orphan Drug Market Regulation

2. ORPHAN DRUG CLINICAL DEVELOPMENT PHASE: UNKNOWN

2.1 Overview
2.2 Orphan Drug Profile in Clinical Phase

3. ORPHAN DRUG CLINICAL DEVELOPMENT PHASE: PRECLINICAL

3.1 Overview
3.2 Orphan Drug Profile in Clinical Phase

4. ORPHAN DRUG CLINICAL DEVELOPMENT PHASE: CLINICAL

4.1 Overview
4.2 Orphan Drug Profile in Clinical Phase

5. ORPHAN DRUG CLINICAL DEVELOPMENT PHASE: PHASE-I

5.1 Overview
5.2 Orphan Drug Profile in Clinical Phase

6. ORPHAN DRUG CLINICAL DEVELOPMENT PHASE: PHASE-I/II

6.1 Overview
6.2 Orphan Drug Profile in Clinical Phase

7. ORPHAN DRUG CLINICAL DEVELOPMENT PHASE: PHASE-II

7.1 Overview
7.2 Orphan Drug Profile in Clinical Phase

8. ORPHAN DRUG CLINICAL DEVELOPMENT PHASE: PHASE-II/III

8.1 Overview
8.2 Orphan Drug Profile in Clinical Phase

9. ORPHAN DRUG CLINICAL DEVELOPMENT PHASE: PHASE-III

9.1 Overview
9.2 Orphan Drug Profile in Clinical Phase

10. ORPHAN DRUG CLINICAL DEVELOPMENT PHASE: PREREGISTRATION

10.1 Overview
10.2 Orphan Drug Profile in Clinical Phase

11. ORPHAN DRUG CLINICAL DEVELOPMENT PHASE: REGISTERED

11.1 Overview
11.2 Orphan Drug Profile in Clinical Phase

12. MARKETED

12.1 Overview
12.2 Marketed Orphan Drug Profile in Market

13. SUSPENDED & DISCONTINUED ORPHAN DRUG PROFILES

13.1 No Development Reported
13.2 Discontinued Orphan Drug Profiles
13.3 Suspended Orphan Drug Profile
13.4 Applications Withdrawl

EACH DRUG PROFILE HAS TABLES REPRESENTING FOLLOWING INFORMATION:
  • Alternate Names
  • Originator & Owner
  • Collaborator
  • Technology Provider
  • Licensee
  • Highest Development Phase
  • Indications
  • Class
  • Mechanism of Action
  • ATC code
  • Designated Brand Name & Orphan Designation

Rare  diseases  are  also  known  as  Orphan  diseases.  These  diseases  are  generally categorized  as  chronic,  degenerative,  and  life-threatening.  As  per  the  official definition, rare diseases are classified as those that affect fewer than 200,000 in the United States and less than 5 in 10,000 in the EU. The term “orphan” was associated with these drugs in order to reflect the lack of interest by pharma companies. In the European  Union,  orphan  drugs  are  known  as  orphan  medicinal  products.  Many treatments  which  are  commercially  available  in  today’s  world  lack  the  ability  to address most of the rare disease indications. This throws open significant potential and opportunities in the European Union and other regions of the world which are currently untapped. 

As the volume of population impacted by rare diseases is very small, the pharma giants have historically not been attracted to a major extent to invest in the development of drugs  required  for  such  rare  diseases.  Historically,  the  development  of  70-75%  of orphan  drugs  was  mostly  in  the  realm  of  smaller  biotechnology  and  specialty pharmaceutical  companies,  and  the  remaining  25-30%  of  the  orphan  drugs  were developed by the pharma giants. However, in the past 2-3 years, the share of pharma giants in the orphan drug approvals has increased to close to 40-45%. Thus, the share of these big pharma companies increased from 53% to 70% in 2009 in the rare diseases market. 

The rare diseases normally include certain cancers, metabolic conditions, diseases of the   nervous   system   and   musculoskeletal   disorders,   which   are   extremely   life-threatening  and  impact  lesser  than  5  people  in  every  10,000  people.  However,  as  a group, these diseases together could possibly affect close to 30 million people directly or indirectly in Europe. This shows the significant of the need to develop an increasing number of orphan medicinal products in the European region.

Additionally, the investment in R&D by the European companies for developing orphan medicinal  products  has  increased  by  more  than  200%,  while  the  total  number  of employees in these companies has recorded an increase of more than 150% since 2000. With  the  long  durations  of  lead  times  in  the  biopharmaceuticals  industry  for  R&D projects, it is most likely that the EU Regulation for Orphan medicinal products would have a significant impact in the coming years.



More Publications